BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Osato MS, Reddy SG, Piergies AA, Bochenek WJ, Testa RT, Graham DY. Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment Pharmacol Ther. 2001;15:487-492. [PMID: 11284777 DOI: 10.1046/j.1365-2036.2001.00957.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Song ZQ, Zhou LY. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication: EMMB therapy for H. pylori eradication. Journal of Digestive Diseases 2016;17:260-7. [DOI: 10.1111/1751-2980.12334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
3 Loughlin MF. Novel therapeutic targets in Helicobacter pylori. Expert Opin Ther Targets 2003;7:725-35. [PMID: 14640908 DOI: 10.1517/14728222.7.6.725] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
4 Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2001;15:1543-1547. [PMID: 11563992 DOI: 10.1046/j.1365-2036.2001.01064.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
5 Li Y, Dannelly HK. Inactivation of the putative tetracycline resistance gene HP1165 in Helicobacter pylori led to loss of inducible tetracycline resistance. Arch Microbiol. 2006;185:255-262. [PMID: 16482431 DOI: 10.1007/s00203-006-0093-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
6 Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Abe T, Sato S, Arita T. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2006;21:262-7. [DOI: 10.1111/j.1440-1746.2006.04183.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
7 Song Z, Suo B, Zhang L, Zhou L. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. Helicobacter. 2016;21:462-470. [PMID: 27060292 DOI: 10.1111/hel.12313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
8 Ren JM, Zou QM, Wang FK, He Q, Chen W, Zen WK. PELA microspheres loaded H. pylori lysates and their mucosal immune response. World J Gastroenterol 2002; 8(6): 1098-1102 [PMID: 12439933 DOI: 10.3748/wjg.v8.i6.1098] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
9 Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, Rivera M, Palladini D, Nardi F, Paoluzi P. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis. 2005;37:571-576. [PMID: 15996628 DOI: 10.1016/j.dld.2005.03.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
10 Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter. 2010;15:154-159. [PMID: 20402818 DOI: 10.1111/j.1523-5378.2009.00739.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
11 Sampaio PS, Calado CRC. Potential of FTIR-Spectroscopy for Drugs Screening against Helicobacter pylori. Antibiotics (Basel) 2020;9:E897. [PMID: 33322665 DOI: 10.3390/antibiotics9120897] [Reference Citation Analysis]
12 Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496. [PMID: 12180896 DOI: 10.2165/00128071-200203070-00005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
13 Funatogawa K, Hayashi S, Shimomura H, Yoshida T, Hatano T, Ito H, Hirai Y. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol Immunol. 2004;48:251-261. [PMID: 15107535 DOI: 10.1111/j.1348-0421.2004.tb03521.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 132] [Article Influence: 9.2] [Reference Citation Analysis]
14 Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007;25:1429-1434. [PMID: 17539982 DOI: 10.1111/j.1365-2036.2007.03331.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
15 Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter. 2002;7 Suppl 1:43-49. [PMID: 12197909 DOI: 10.1046/j.1523-5378.7.s1.7.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]